FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220711549> ?p ?o ?g. }

• W4220711549 abstract "Ovarian cancer is initially responsive to frontline chemotherapy. Unfortunately, it often recurs and becomes resistant to available therapies and the survival rate for advanced and recurrent ovarian cancer is unacceptably low. We thus hypothesized that it would be possible to achieve more durable treatment responses by combining cisplatin chemotherapy with SW IV-134, a cancer-targeted peptide mimetic and inducer of cell death. SW IV-134 is a recently developed small molecule conjugate linking a sigma-2 ligand with a peptide analog (mimetic) of the intrinsic death pathway activator SMAC (second-mitochondria activator of caspases). The sigma-2 receptor is overexpressed in ovarian cancer and the sigma-2 ligand portion of the conjugate facilitates cancer selectivity. The effector portion of the conjugate is expected to synergize with cisplatin chemotherapy and the cancer selectivity is expected to reduce putative off-target toxicities.Ovarian cancer cell lines were treated with cisplatin alone, SW IV-134 alone and a combination of the two drugs. Treatment efficacy was determined using luminescent cell viability assays. Caspase-3/7, - 8 and - 9 activities were measured as complementary indicators of death pathway activation. Syngeneic mouse models and patient-derived xenograft (PDX) models of human ovarian cancer were studied for response to SW IV-134 and cisplatin monotherapy as well as combination therapy. Efficacy of the therapy was measured by tumor growth rate and survival as the primary readouts. Potential drug related toxicities were assessed at necropsy.The combination treatment was consistently superior in multiple cell lines when compared to the single agents in vitro. The expected mechanism of tumor cell death, such as caspase activation, was confirmed using luminescent and flow cytometry-based assay systems. Combination therapy proved to be superior in both syngeneic and PDX-based murine models of ovarian cancer. Most notably, combination therapy resulted in a complete resolution of established tumors in all study animals in a patient-derived xenograft model of ovarian cancer.The addition of SW IV-134 in combination with cisplatin chemotherapy represents a promising treatment option that warrants further pre-clinical development and evaluation as a therapy for women with advanced ovarian cancer." @default.
• W4220711549 created "2022-04-03" @default.
• W4220711549 creator A5013020518 @default.
• W4220711549 creator A5046107872 @default.
• W4220711549 creator A5056113124 @default.
• W4220711549 creator A5060050760 @default.
• W4220711549 creator A5061406535 @default.
• W4220711549 creator A5076087889 @default.
• W4220711549 creator A5080722354 @default.
• W4220711549 creator A5088286796 @default.
• W4220711549 creator A5089554127 @default.
• W4220711549 creator A5002287278 @default.
• W4220711549 date "2022-03-12" @default.
• W4220711549 modified "2023-09-23" @default.
• W4220711549 title "The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer" @default.
• W4220711549 cites W1781170077 @default.
• W4220711549 cites W1978074643 @default.
• W4220711549 cites W1983243856 @default.
• W4220711549 cites W1996970031 @default.
• W4220711549 cites W1997743035 @default.
• W4220711549 cites W2042409437 @default.
• W4220711549 cites W2065785794 @default.
• W4220711549 cites W2076899379 @default.
• W4220711549 cites W2089351812 @default.
• W4220711549 cites W2097777938 @default.
• W4220711549 cites W2106767659 @default.
• W4220711549 cites W2122224354 @default.
• W4220711549 cites W2130941707 @default.
• W4220711549 cites W2135947389 @default.
• W4220711549 cites W2137149567 @default.
• W4220711549 cites W2138035969 @default.
• W4220711549 cites W2154175915 @default.
• W4220711549 cites W2162645859 @default.
• W4220711549 cites W2168893449 @default.
• W4220711549 cites W2199178706 @default.
• W4220711549 cites W2274012164 @default.
• W4220711549 cites W2299895389 @default.
• W4220711549 cites W236091721 @default.
• W4220711549 cites W2557071593 @default.
• W4220711549 cites W2572164004 @default.
• W4220711549 cites W2602708867 @default.
• W4220711549 cites W2605995955 @default.
• W4220711549 cites W2801550274 @default.
• W4220711549 cites W2899760849 @default.
• W4220711549 cites W2904675051 @default.
• W4220711549 cites W2905532256 @default.
• W4220711549 cites W2914255007 @default.
• W4220711549 cites W2937594202 @default.
• W4220711549 cites W2951714360 @default.
• W4220711549 cites W2953658820 @default.
• W4220711549 cites W2986121700 @default.
• W4220711549 cites W2994977341 @default.
• W4220711549 cites W2999417355 @default.
• W4220711549 cites W3016364201 @default.
• W4220711549 cites W3035853607 @default.
• W4220711549 cites W3047016852 @default.
• W4220711549 cites W3047211484 @default.
• W4220711549 cites W3155089045 @default.
• W4220711549 cites W3191679899 @default.
• W4220711549 doi "https://doi.org/10.1186/s12885-022-09367-w" @default.
• W4220711549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35279106" @default.
• W4220711549 hasPublicationYear "2022" @default.
• W4220711549 type Work @default.
• W4220711549 citedByCount "2" @default.
• W4220711549 countsByYear W42207115492022 @default.
• W4220711549 countsByYear W42207115492023 @default.
• W4220711549 crossrefType "journal-article" @default.
• W4220711549 hasAuthorship W4220711549A5002287278 @default.
• W4220711549 hasAuthorship W4220711549A5013020518 @default.
• W4220711549 hasAuthorship W4220711549A5046107872 @default.
• W4220711549 hasAuthorship W4220711549A5056113124 @default.
• W4220711549 hasAuthorship W4220711549A5060050760 @default.
• W4220711549 hasAuthorship W4220711549A5061406535 @default.
• W4220711549 hasAuthorship W4220711549A5076087889 @default.
• W4220711549 hasAuthorship W4220711549A5080722354 @default.
• W4220711549 hasAuthorship W4220711549A5088286796 @default.
• W4220711549 hasAuthorship W4220711549A5089554127 @default.
• W4220711549 hasBestOaLocation W42207115491 @default.
• W4220711549 hasConcept C121608353 @default.
• W4220711549 hasConcept C126322002 @default.
• W4220711549 hasConcept C143998085 @default.
• W4220711549 hasConcept C190283241 @default.
• W4220711549 hasConcept C2776694085 @default.
• W4220711549 hasConcept C2778239845 @default.
• W4220711549 hasConcept C2780427987 @default.
• W4220711549 hasConcept C31573885 @default.
• W4220711549 hasConcept C502942594 @default.
• W4220711549 hasConcept C55493867 @default.
• W4220711549 hasConcept C71924100 @default.
• W4220711549 hasConcept C86803240 @default.
• W4220711549 hasConcept C96232424 @default.
• W4220711549 hasConcept C98274493 @default.
• W4220711549 hasConceptScore W4220711549C121608353 @default.
• W4220711549 hasConceptScore W4220711549C126322002 @default.
• W4220711549 hasConceptScore W4220711549C143998085 @default.
• W4220711549 hasConceptScore W4220711549C190283241 @default.
• W4220711549 hasConceptScore W4220711549C2776694085 @default.
• W4220711549 hasConceptScore W4220711549C2778239845 @default.
• W4220711549 hasConceptScore W4220711549C2780427987 @default.
• W4220711549 hasConceptScore W4220711549C31573885 @default.

• next